Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 4 min read

What is glycosaminoglycans?

Glycosaminoglycans are a class of long, negatively charged polysaccharides of the extracellular matrix. This page summarises research on their structure, regulation and roles in cardiac, dermal, joint and mucosal models.

peptides-pro Editorial

Glycosaminoglycans (GAGs) are a class of long, unbranched, negatively charged polysaccharides that are major components of the extracellular matrix (ECM). They are also referred to as mucopolysaccharides. GAGs are composed of repeating disaccharide units, typically containing an amino sugar (N-acetylglucosamine or N-acetylgalactosamine) and a uronic acid (glucuronic acid or iduronic acid), with varying degrees of sulfation. Common GAG subclasses include heparan sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic acid. In the ECM, GAGs are often covalently attached to core proteins to form proteoglycans, such as decorin and syndecan-1 [1][4][8]. The evidence block does not provide a specific sequence, formula or molecular weight for the class as a whole.

Research on GAGs centres on their regulation by peptide factors and their roles in ECM remodelling, with pathways including kisspeptin receptor signalling in cardiac fibroblasts [1] and growth-factor-related peptide activity in dermal models [2].

Research Studies

Kisspeptin-10 and glycosaminoglycan and decorin content in human cardiac fibroblast cultures

In human cardiac fibroblast cultures, kisspeptin-10 (KiSS-10) was studied for its effects on glycosaminoglycan and decorin content. The study assessed GAG levels by the Farndale method and decorin secretion, with or without signalling inhibitors, to identify the mechanism. The findings indicate that KiSS-10 regulates these ECM components in this in vitro model [1].

GHK and collagen and glycosaminoglycan synthesis in skin

Glycyl-histidyl-lysine (GHK) is a tripeptide studied for topical anti-wrinkle applications. In preclinical and in vitro contexts, GHK has been reported to enhance collagen and glycosaminoglycan synthesis, as well as to increase nerve outgrowth and angiogenesis. Its derivatives, GHK-Cu (a copper complex) and Pal-GHK (a palmitoylated form), are used in cosmetic products. The evidence notes that while GHK has several properties from wound healing to wrinkle reduction, problems and limitations exist for topical use [2].

Chondroitin sulfate and osteoarthritis burden in adults

Chondroitin sulfate (CS) is a glycosaminoglycan and a major ECM component of proteoglycans. It is classified as a Symptomatic Slow Acting Drug for Osteoarthritis (SYSADOA). An observational, descriptive, prospective, national study (TRUST) is being conducted to describe the burden of osteoarthritis and quality of life in adult patients in Poland treated with Structum® (a chondroitin sulfate product) [4].

CACIPLIQ20 and wound healing in subjects with epidermolysis bullosa

Epidermolysis bullosa (EB) is a group of inherited disorders characterised by skin and mucous membrane fragility. A clinical study is evaluating CACIPLIQ20, which contains heparan sulfate, for wound healing in subjects with EB. The rationale includes the role of heparan sulfates as key elements in the basement membrane zone [3].

Glycocalyx degradation and circulating unmeasured ions after cardiopulmonary bypass

A prospective subanalysis embedded in a randomised trial examined whether endothelial glycocalyx degradation is associated with increased circulating unmeasured anions after cardiopulmonary bypass. The study reports that release of polyanionic heparan sulfate fragments may contribute to this unexplained anionic burden [5].

GHK-Cu and regenerative potential in aesthetic medicine

In preclinical models, GHK-Cu has demonstrated regenerative, anti-inflammatory and antioxidant properties. The evidence reports that these findings have prompted increasing integration of GHK-Cu into aesthetic medicine, although the source is a review and the observations are preclinical [6].

Proteoglycans and bone metastasis

Proteoglycans, which include glycosaminoglycan chains, are studied as molecular regulators of bone metastasis. In breast and prostate cancer, bone metastasis involves complex interactions among tumour cells, bone-resident cells, immune populations, vascular components and the ECM. The evidence describes proteoglycans as participants in ECM remodelling, tumour-bone crosstalk and dormancy [7].

Syndecan-1 and mucosal homeostasis in inflammatory bowel disease

The intestinal proteoglycan Syndecan-1 (SDC1) has been implicated in inflammatory bowel disease (IBD)-associated barrier dysfunction and inflammation. A study aimed to elucidate how intestinal epithelial SDC1 maintains mucosal homeostasis, reporting that it enhances Faecalibacterium prausnitzii biofilm formation [8].

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp